Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Phase 1

Obe-cel in Adolescent [Applicable in UK Only] and Adult Severe, Refractory Systemic Lupus Erythematosus

NCT06333483 · tracked via the Priya Life Science Spain tracker
Phase
Phase 1
Started
2024-02-02
Last updated
2026-07-31

Condition(s) studied

Systemic Lupus Erythematosus

Investigational drug(s) / intervention(s)

Obecabtagene autoleucel (obe-cel) →

Obecabtagene autoleucel (obe-cel): Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with a single dose of obe-cel

Study summary

This is a Phase 1 study of obecabtagene autoleucel (obe-cel), autologous T cells engineered with a chimeric antigen receptor (CAR) targeting CD19, to establish the tolerability, safety, preliminary efficacy, and pharmacokinetics of obe-cel in patients with severe, refractory SLE.

Eligibility

Sex
ALL
Min age
12 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: -Key Inclusion Criteria- * Women or men ≥ 18 years at screening \[Spain only\] or patients 12 to 65 years of age (inclusive) at the time of signing the informed consent \[UK only\] * Diagnosis of SLE fulfilling the 2019 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) Classification Criteria for Systemic Lupus Erythematosus * Positive for at least one of the following autoantibodies: antinuclear antibodies (ANA) at a titer of ≥ 1:80, or anti-dsDNA (≥ 30 IU/mL) or anti-Smith (\> upper limit of normal \[ULN\]), anti-histone or anti-chromatin (\> ULN) * Severe, refractory SLE Exclusion Criteria: -Key Exclusion Criteria- * Medications * Within 2 months of leukapheresis: use of anti-CD20 therapy * Prior treatment with anti-CD19 therapy (including bispecifics), adoptive T cell therapy or any prior gene therapy product (e.g., CAR T cell therapy) * Immunization with a live or attenuated vaccine within 2 months of leukapheresis * SLE and Autoimmunity: * Recurrent neuropsychiatric lupus or active, severe or unstable neuropsychiatric lupus within 2 years from screening * Diagnosis of drug-induced SLE rather than idiopathic SLE * Any acute, severe lupus-related flare during screening that needs immediate treatment and/or makes the immunosuppressive washout impossible; thus, making the patient ineligible for CD19 CAR T therapy as judged by the Investigator or Sponsor * Significant, likely irreversible organ damage related to SLE (e.g., end-stage renal disease) that in the opinion of the Investigator renders CD19 CAR T cell therapy unlikely to benefit the patient * Diagnosis of another non-SLE autoimmune disease (e.g., dermatomyositis, polymyositis, scleroderma, rheumatoid arthritis) or overlap syndrome * Medical History: * History or presence of: (Within 3 months before screening visit) * Clinically relevant central nervous system (CNS) pathology such as epilepsy, paresis, aphasia, or stroke * Evidence of deep venous thrombosis or pulmonary embolism * History or presence of severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, uncontrolled mental illness, or psychosis * Clinically significant, uncontrolled heart disease not due to SLE (New York Heart Association Class III or IV heart failure, uncontrolled angina, severe uncontrolled cardiac arrhythmia, or electrocardiographic evidence of acute ischemia or Grade 3 conduction system abnormalities unless the patient has a pacemaker) or a recent (within 12 months of screening) cardiac event * Active or uncontrolled fungal, bacterial, viral (including COVID-19), or other infection requiring systemic antimicrobials for management * Active or latent hepatitis B or active hepatitis C * Human immunodeficiency virus, human T-cell leukemia virus (HTLV)-1, HTLV-2 or syphilis positive test at screening * History of malignant neoplasms unless disease free for at least 24 months (basal cell or squamous cell carcinoma in situ, or in situ breast cancer on hormonal therapy allowed) * History of heart, lung, kidney, liver transplant or hematopoietic stem cell transplant * Pregnancy or lactating * Laboratory and Organ Function: * Left ventricular ejection fraction \< 45% (or \< institute's lower limit of normal) confirmed by echocardiogram * Oxygen saturation (SpO2) \< 90% in the absence of oxygen support * B cell aplasia

Primary outcome measure(s)

  • Dose-limiting toxicities — Up to 28 days from obe-cel infusion
    Percentage of patients receiving obe-cel who experience dose-limiting toxicities (DLTs)
  • Adverse events — Up to Month 12
    Adverse event (AE) type, frequency, severity, and relationship with obe-cel and lymphodepletion of AEs

Trial sites (6)

FacilityCityRegionStatus
Hospital Universitari Vall Hebrón Barcelona Spain
Hospital Universitari i Politecnic La Fe Valencia Spain
Addenbrookes Hospital Cambridge United Kingdom
University College London Hospitals NHS Foundation Trust London United Kingdom
Great Ormond Street Hospital London United Kingdom
Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester United Kingdom
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06333483 on ClinicalTrials.gov ↗ ← All trials in Spain